At a glance
ClinicalIndex Comparison RecordN/ACompleted· 108 enrolled
Drug / intervention
Enantone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty
In Brief
An observational study evaluating Enantone and GnRH agonist for Central Precocious Puberty. Completed, enrolled 108 participants across 6 sites.
Detailed Summary
The purpose of this study is to evaluate the long-term safety and efficacy of Enantone in the treatment of CPP in Chinese participants.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Precocious Puberty
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartJun 2017
Primary CompletionSep 2018
TodayJul 2026
First PostedDec 15, 2016
Enrollment StartJun 24, 2017
Primary CompletionSep 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.5 years ago
Interventions
Enantonedrug
Enantone suspension for injection
GnRH agonistdrug
A non-Enantone GnRH agonist